⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38657464 | 0.79 | IRAK4 (0.31) | — | |
| SCHEMBL22687312 | 0.79 | P2RX7 (0.31) | — | |
| SCHEMBL28882155 | 0.77 | MAPK1 (0.33) | — | |
| SCHEMBL28412942 | 0.75 | MAPK1 (0.30) | — | |
| SCHEMBL25199539 | 0.75 | JAK1 (0.32) | — | |
| SCHEMBL29674195 | 0.75 | MAPK1 (0.31) | — | |
| SCHEMBL19638707 | 0.73 | MAPK1 (0.31) | — | |
| SCHEMBL21001854 | 0.71 | MAPK8 (0.30) | — | |
| SCHEMBL3469250 | 0.71 | MAPK8 (0.30) | — | |
| SCHEMBL17713790 | 0.71 | PRKAG1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4376841-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11919917-B2 | Sting agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| US-20230339992-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4185588-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2023-05-31 | — | — | EP | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4134098-A1 | METHOD OF CANCER THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| CN-114245794-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210363166-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-25 | — | — | US | disclosed |
| CN-113677664-A | Tricyclic degradants of IKAROS and AIOLOS | C4医药公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11130773-B2 | STING agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20210253615-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| CN-112654625-A | Heterocyclic and heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112203653-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |